Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $20.44, gaining 72.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 33.46 indicates a 63.7% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $24.02. While the lowest estimate of$ 8.00 indicates a 60.9% decline from the current price level, the most optimisti ...